Follow The Filings

Insider trades

Stock that executives, directors and 10% owners bought and sold on the open market, from the Form 4s they file with the SEC within two business days. Grants, option exercises and shares sold to cover taxes are left out.

4,839 companies covered, latest filing Oct 23.

  • $79.2M bought by 61 insiders at 47 companies
  • $239M sold by 49 insiders outside a trading plan
  • $2.5B sold by 203 insiders under 10b5-1 plans
  • 10 companies where two or more insiders bought (30 days)

Biggest buys

Past week, each insider's filings added up.

  1. CRBGCorebridge Financial
    Life Insurance Co Nippon10% owner
    1,430,631 shares at $34.37 Oct 15–21, 5 filings +1.1% to stake 2 superinvestors bought in Q2
    $49.2M
  2. DOLEDole PLC
    Pale Fire Capital SE10% owner, +4 joint filers
    648,356 shares at $13.19 Oct 20–22 +6.7% to stake
    $8.6M
  3. APLDApplied Digital
    Jason Gechen ZhangPresident
    300,000 shares at $18.86 Oct 16 +12% to stake 5 superinvestors bought in Q2
    $5.7M
  4. RENTRent the Runway
    STORY3 Capital Partners, LLCDirector, +3 joint filers
    632,922 shares at $3.55 Oct 21 +15% to stake
    $2.2M
  5. RENTRent the Runway
    CHS US Investments LLC10% owner, +4 joint filers
    458,245 shares at $3.55 Oct 21 +2% to stake
    $1.6M
  6. FBKFB Financial
    Orrin H Ingram IIDirector
    29,081 shares at $52.88 Oct 20 +31% to stake
    $1.5M
  7. TENXTenax Therapeutics
    ADAR1 Capital Management, LLC10% owner, +1 joint filer
    922,849 shares at $1.59 Oct 19–21 +14% to stake
    $1.5M
  8. APLDApplied Digital
    Wes CumminsCEO
    55,803 shares at $18.04 Oct 16 +1% to stake 5 superinvestors bought in Q2
    $1M
  9. RAPPRapport Therapeutics
    Steven M PaulDirector
    35,714 shares at $27.28 Oct 22 +86% to stake
    $974K
  10. SNESSenesTech
    Glenbrook Capital Management10% owner
    1,087,679 shares at $0.7200 Oct 15–22, 2 filings
    $781K

Biggest sales

Past week, each insider's filings added up. Planned sales are marked.

  1. IHTInnSuites Hospitality Trust
    James F WirthCEO
    43,111 shares at $46,654.38 Oct 20 0.5% of stake Planned sale (10b5-1)
    $2B
  2. SNOWSnowflake
    Frank SlootmanDirector
    300,000 shares at $316.43 Oct 19 94% of stake Planned sale (10b5-1)
    $94.9M
  3. TALOTalos Energy
    Empresarial De Capitales S.a. De C.v. Control10% owner
    4,893,590 shares at $17.55 Oct 15–19, 2 filings 17% of stake
    $85.9M
  4. TRVTravelers
    Alan D SchnitzerCEO
    88,900 shares at $396.77 Oct 21 23% of stake
    $35.3M
  5. PATHUiPath
    Daniel DinesCEO
    2,500,000 shares at $13.23 Oct 15–16 7.9% of stake Planned sale (10b5-1)
    $33.1M
  6. UTHRUnited Therapeutics
    Martine A RothblattCEO
    47,500 shares at $555.06 Oct 16–22, 5 filings 13% of stake Planned sale (10b5-1)
    $26.4M
  7. MUMicron Technology
    Scott J DeboerPres. & Chief Tech & Prod Offr
    28,545 shares at $900.00 Oct 16 16% of stake Planned sale (10b5-1)
    $25.7M
  8. ALMRAlamar Biosciences
    Qiming Corporate GP VI, Ltd.10% owner, +6 joint filers
    733,811 shares at $28.64 Oct 15–22, 3 filings 29% of stake
    $21M
  9. SNOWSnowflake
    Benoit DagevilleDirector
    50,000 shares at $321.74 Oct 21 2.1% of stake Planned sale (10b5-1)
    $16.1M
  10. LINDLindblad Expeditions
    Sven-Olof LindbladDirector
    403,674 shares at $35.31 Oct 16–22, 2 filings 3.8% of stake Planned sale (10b5-1)
    $14.3M

Cluster buying

Companies where two or more insiders bought on the open market in the last 30 days, most buyers first

  1. TSMTaiwan Semiconductor 19 insiders, $80K

    Che-Chia Wei CEO, Yuh-Jier Mii COO, Yung-Pei Chin COO, Yung-Chin Hou COO, +15 more

    Latest buy Oct 7 19 executives 20 superinvestors sold in Q2
  2. SPGSimon Property Group 11 insiders, $461K

    Reuben S Leibowitz Director, Larry C Glasscock Director, Daniel C. Smith Director, Gary M Rodkin Director, +7 more

    Latest buy Sep 30
  3. FULH. B. Fuller 9 insiders, $1.1M

    R Jeffrey Bailly Director, Daniel L Florness Director, Srilata Zaheer Director, Charles T Lauber Director, +5 more

    Latest buy Oct 16 1 executive 1 superinvestor bought in Q2
  4. RAPPRapport Therapeutics 6 insiders, $1.7M

    Steven M Paul Director, John Maraganore Director, Troy A. Ignelzi CFO, Wendy B. Young Director, +2 more

    Latest buy Oct 23 1 executive
  5. ATCHAtlasClear 5 insiders, $163K

    Thomas Jon Hammond Director, Sandip I Patel CFO, John Martin Schaible Chair, David Craig Ridenhour President, +1 more

    Latest buy Sep 25 3 executives
  6. RGCORGC Resources 5 insiders, $85K

    John B Williamson III Director, Robert B Johnston Director, Paul W Nester CEO, Lawrence T. Oliver Senior VP and Secretary, +1 more

    Latest buy Oct 1 3 executives
  7. WVVIWillamette Valley Vineyards 5 insiders, $75K

    Michael Jordan Osborn CEO, John Walter Hazlett CFO, Gregory William Voorhies Director, James W Bernau President, +1 more

    Latest buy Oct 12 3 executives
  8. MPBMid Penn Bancorp 5 insiders, $25K

    Matthew G De Soto Director, Albert J. Evans Director, Joel L. Frank Director, Theodore W Mowery Director, +1 more

    Latest buy Sep 30
  9. DXDynex Capital 4 insiders, $245K

    Smriti Laxman Popenoe CEO, Byron L Boston CEO, Terrence John Connelly Jr. Chief Investment Officer, Michael Andrew Sartori CFO

    Latest buy Oct 20 4 executives
  10. ANIXAnixa Biosciences 4 insiders, $203K

    Lewis H Titterton Jr. Director, Amit Kumar CEO, Michael Catelani CFO, Arnold M Baskies Director

    Latest buy Oct 22 2 executives

PTCT insider trades

Every open-market buy and sale in PTCT, one row per filing, newest first

PTCT page
All Buys Sales
Everyone CEOs CFOs Executives Directors 10% owners
Any size $100K+ $1M+ $10M+
Hide planned sales
  1. Michael Schmertzler Director
    PTCTPTC Therapeutics
    Planned sale
    $149K 2,500 shares at $59.61 0.2% of stake
    Traded Oct 14 Filed Oct 16
    ↗
  2. Mark Elliott Boulding Exec. VP and CLO
    PTCTPTC Therapeutics
    Planned sale
    $12K 192 shares at $64.26 0.2% of stake
    Traded Oct 9 Filed Oct 13
    ↗
  3. Michael Schmertzler Director
    PTCTPTC Therapeutics
    Planned sale
    $158K 2,500 shares at $63.39 0.2% of stake
    Traded Oct 7 Filed Oct 9
    ↗
  4. Mark Elliott Boulding Exec. VP and CLO
    PTCTPTC Therapeutics
    Planned sale
    $133K 2,073 shares at $64.06 1.9% of stake
    Traded Oct 5–6 Filed Oct 7
    ↗
  5. Glenn Steele Jr. MD PHD Director
    PTCTPTC Therapeutics
    Planned sale
    $782K 12,000 shares at $65.16 35% of stake
    Traded Sep 30 Filed Oct 2
    ↗
  6. Michael Schmertzler Director
    PTCTPTC Therapeutics
    Planned sale
    $1.3M 20,000 shares at $67.49 1.5% of stake
    Traded Sep 16–17 Filed Sep 18
    ↗
  7. Michael Schmertzler Director
    PTCTPTC Therapeutics
    Planned sale
    $1.4M 20,000 shares at $67.59 1.5% of stake
    Traded Sep 9–10 Filed Sep 11
    ↗
  8. Michael Schmertzler Director
    PTCTPTC Therapeutics
    Planned sale
    $1.8M 25,000 shares at $72.26 1.8% of stake
    Traded Aug 26–27 Filed Aug 28
    ↗
  9. Michael Schmertzler Director
    PTCTPTC Therapeutics
    Planned sale
    $1.8M 25,000 shares at $72.22 1.8% of stake
    Traded Aug 19–20 Filed Aug 21
    ↗
  10. Mark Elliott Boulding Exec. VP and CLO
    PTCTPTC Therapeutics
    Planned sale
    $204K 2,813 shares at $72.57 2.6% of stake
    Traded Aug 17 Filed Aug 19
    ↗
  11. Mary L. Smith Director
    PTCTPTC Therapeutics
    Planned sale
    $1.4M 15,834 shares at $90.00 42% of stake
    Traded Jul 9 Filed Jul 13
    ↗
  12. Neil Gregory Almstead Chief Technical Ops Officer
    PTCTPTC Therapeutics
    Planned sale
    $222K 2,464 shares at $90.25 3.9% of stake
    Traded Jul 9 Filed Jul 13
    ↗
  13. Mark Elliott Boulding Exec. VP and CLO
    PTCTPTC Therapeutics
    Planned sale
    $432K 5,079 shares at $85.08 4.6% of stake
    Traded Jul 6 Filed Jul 8
    ↗
  14. Neil Gregory Almstead Chief Technical Ops Officer
    PTCTPTC Therapeutics
    Planned sale
    $4.1M 46,774 shares at $87.52 44% of stake
    Traded Jul 6–7 Filed Jul 8
    ↗
  15. Neil Gregory Almstead Chief Technical Ops Officer
    PTCTPTC Therapeutics
    Planned sale
    $693K 8,130 shares at $85.26 12% of stake
    Traded Jun 26 Filed Jun 30
    ↗
  16. Neil Gregory Almstead Chief Technical Ops Officer
    PTCTPTC Therapeutics
    Planned sale
    $2.3M 26,283 shares at $85.78 30% of stake
    Traded Jun 24–25 Filed Jun 26
    ↗
  17. Neil Gregory Almstead Chief Technical Ops Officer
    PTCTPTC Therapeutics
    Planned sale
    $1.9M 23,749 shares at $80.90 28% of stake
    Traded Jun 22 Filed Jun 24
    ↗
  18. Christine Marie Utter SVP, Chief Accounting Officer
    PTCTPTC Therapeutics
    Planned sale
    $1.5M 19,686 shares at $75.56 22% of stake
    Traded Jun 17 Filed Jun 22
    ↗
  19. Mark Elliott Boulding Exec. VP and CLO
    PTCTPTC Therapeutics
    Planned sale
    $823K 10,462 shares at $78.65 9% of stake
    Traded Jun 17 Filed Jun 22
    ↗
  20. Eric Pauwels Chief Business Officer
    PTCTPTC Therapeutics
    Planned sale
    $1.6M 21,277 shares at $75.00 23% of stake
    Traded Jun 10 Filed Jun 12
    ↗
  21. Mark Elliott Boulding Exec. VP and CLO
    PTCTPTC Therapeutics
    Planned sale
    $203K 2,812 shares at $72.18 2.6% of stake
    Traded May 15 Filed May 19
    ↗
  22. Matthew B. Klein CEO
    PTCTPTC Therapeutics
    Planned sale
    $731K 10,000 shares at $73.08 2.5% of stake
    Traded May 14 Filed May 15
    ↗
  23. Mark Elliott Boulding Exec. VP and CLO
    PTCTPTC Therapeutics
    Planned sale
    $280K 3,540 shares at $78.97 3.3% of stake
    Traded May 8 Filed May 12
    ↗
  24. Mark Elliott Boulding Exec. VP and CLO
    PTCTPTC Therapeutics
    Planned sale
    $157K 2,265 shares at $69.45 2.1% of stake
    Traded Apr 6 Filed Apr 8
    ↗
  25. Neil Gregory Almstead Chief Technical Ops Officer
    PTCTPTC Therapeutics
    Planned sale
    $3.6M 52,003 shares at $69.04 46% of stake
    Traded Apr 1 Filed Apr 3
    ↗
  26. Stephanie Okey Director
    PTCTPTC Therapeutics
    Planned sale
    $1.1M 15,167 shares at $70.00 66% of stake
    Traded Mar 10 Filed Mar 12
    ↗
  27. Stephanie Okey Director
    PTCTPTC Therapeutics
    Planned sale
    $401K 6,333 shares at $63.38 44% of stake
    Traded Mar 5 Filed Mar 9
    ↗
  28. Lee Scott Golden EVP & Chief Medical Officer
    PTCTPTC Therapeutics
    Planned sale
    $634K 10,000 shares at $63.38 11% of stake
    Traded Mar 5 Filed Mar 9
    ↗
  29. Neil Gregory Almstead Chief Technical Ops Officer
    PTCTPTC Therapeutics
    Planned sale
    $253K 3,989 shares at $63.38 59% of stake
    Traded Mar 5 Filed Mar 9
    ↗
  30. Mark Elliott Boulding Exec. VP and CLO
    PTCTPTC Therapeutics
    Planned sale
    $210K 3,019 shares at $69.48 2.8% of stake
    Traded Feb 19 Filed Feb 23
    ↗
  31. Mark Elliott Boulding Exec. VP and CLO
    PTCTPTC Therapeutics
    Planned sale
    $195K 2,813 shares at $69.29 2.5% of stake
    Traded Feb 17 Filed Feb 19
    ↗
  32. Mark Elliott Boulding Exec. VP and CLO
    PTCTPTC Therapeutics
    Planned sale
    $391K 5,061 shares at $77.21 4.3% of stake
    Traded Jan 8–9 Filed Jan 12
    ↗
  33. Eric Pauwels Chief Business Officer
    PTCTPTC Therapeutics
    Planned sale
    $455K 5,894 shares at $77.16 6.9% of stake
    Traded Jan 8–12 Filed Jan 12
    ↗
  34. Mark Elliott Boulding Exec. VP and CLO
    PTCTPTC Therapeutics
    Planned sale
    $261K 3,376 shares at $77.42 2.8% of stake
    Traded Jan 7 Filed Jan 8
    ↗
  35. Emma Reeve Director
    PTCTPTC Therapeutics
    Planned sale
    $56K 734 shares at $76.00 6.4% of stake
    Traded Jan 5 Filed Jan 6
    ↗
  36. Mark Elliott Boulding Exec. VP and CLO
    PTCTPTC Therapeutics
    Planned sale
    $171K 2,266 shares at $75.55 1.8% of stake
    Traded Jan 5 Filed Jan 6
    ↗
  37. Glenn Steele Jr. MD PHD Director
    PTCTPTC Therapeutics
    Planned sale
    $916K 12,000 shares at $76.35 39% of stake
    Traded Jan 2 Filed Jan 6
    ↗
  38. Eric Pauwels Chief Business Officer
    PTCTPTC Therapeutics
    Planned sale
    $1.6M 20,508 shares at $77.26 23% of stake
    Traded Dec 19, 2025 Filed Dec 23, 2025
    ↗
  39. Eric Pauwels Chief Business Officer
    PTCTPTC Therapeutics
    Planned sale
    $3.3M 43,492 shares at $75.40 38% of stake
    Traded Dec 17–18 Filed Dec 19, 2025
    ↗
  40. Emma Reeve Director
    PTCTPTC Therapeutics
    Planned sale
    $58K 733 shares at $78.62 9.9% of stake
    Traded Dec 3, 2025 Filed Dec 5, 2025
    ↗
  41. Allan Steven Jacobson Director
    PTCTPTC Therapeutics
    Planned sale
    $2.1M 26,000 shares at $82.00 60% of stake
    Traded Nov 24–25 Filed Nov 26, 2025
    ↗
  42. Neil Gregory Almstead Chief Technical Ops Officer
    PTCTPTC Therapeutics
    Planned sale
    $6M 71,928 shares at $83.44 42% of stake
    Traded Nov 25, 2025 Filed Nov 26, 2025
    ↗
  43. Neil Gregory Almstead Chief Technical Ops Officer
    PTCTPTC Therapeutics
    Planned sale
    $2.9M 35,572 shares at $80.18 26% of stake
    Traded Nov 24, 2025 Filed Nov 26, 2025
    ↗
  44. Emma Reeve Director
    PTCTPTC Therapeutics
    Planned sale
    $795K 10,000 shares at $79.50 60% of stake
    Traded Nov 21, 2025 Filed Nov 25, 2025
    ↗
  45. Mark Elliott Boulding Exec. VP and CLO
    PTCTPTC Therapeutics
    Planned sale
    $214K 2,812 shares at $75.99 2.6% of stake
    Traded Nov 17, 2025 Filed Nov 19, 2025
    ↗
  46. Emma Reeve Director
    PTCTPTC Therapeutics
    Planned sale
    $546K 7,333 shares at $74.50 52% of stake
    Traded Nov 12, 2025 Filed Nov 14, 2025
    ↗
  47. Emma Reeve Director
    PTCTPTC Therapeutics
    Planned sale
    $1.1M 15,666 shares at $69.50 70% of stake
    Traded Oct 30, 2025 Filed Oct 31, 2025
    ↗
  48. Mark Elliott Boulding Exec. VP and CLO
    PTCTPTC Therapeutics
    Planned sale
    $214K 3,375 shares at $63.43 3.1% of stake
    Traded Oct 7, 2025 Filed Oct 9, 2025
    ↗

About this data

  • Officers, directors and anyone owning more than 10% of a company must report a trade in its stock on a Form 4 within two business days. We read each filing from SEC EDGAR and link to it on every row.
  • Only open-market purchases and sales of common stock count here. Stock grants, option exercises, gifts and shares withheld or sold to pay taxes on vesting awards are not decisions to buy or sell, so they are left out.
  • A planned sale was made under a Rule 10b5-1 trading plan, which the insider set up months in advance. Many executives sell this way on a schedule, so a planned sale says less than one made on the day.
  • Values are shares times the price reported. When a filing amends an earlier one, the amended trades replace the originals. Related owners (a fund and its manager) who report the same trade separately are shown once.
  • We cover the 4,839 US companies on our earnings calendar, with a year of history. The superinvestor notes count the featured 13F managers who added or cut the stock in their latest quarter.